Point72 Asset Management L.P. Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Point72 Asset Management L.P. acquired a new position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 849,621 shares of the biotechnology company's stock, valued at approximately $7,630,000. Point72 Asset Management L.P. owned about 0.59% of Aurinia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $135,000. Arrowstreet Capital Limited Partnership purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $9,662,000. Price T Rowe Associates Inc. MD increased its holdings in Aurinia Pharmaceuticals by 19.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 8,350 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Aurinia Pharmaceuticals by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after acquiring an additional 112,113 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

AUPH stock traded down $0.19 during mid-day trading on Friday, reaching $8.08. 2,007,945 shares of the company traded hands, compared to its average volume of 1,333,749. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company has a market capitalization of $1.09 billion, a P/E ratio of -53.86 and a beta of 1.16. Aurinia Pharmaceuticals Inc. has a 52-week low of $5.11 and a 52-week high of $10.67. The company has a fifty day moving average price of $8.02 and a 200-day moving average price of $8.28.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, COO Matthew Maxwell Donley sold 65,902 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the transaction, the chief operating officer now owns 739,456 shares of the company's stock, valued at $5,915,648. The trade was a 8.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. This trade represents a 5.13% decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.